| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 07/13/2005 | EP1551444A2 Method for treatment of demyelinating central nervous system disease using gm-csf |
| 07/13/2005 | EP1551424A1 Treatment of neurological disorders by dsrna adminitration |
| 07/13/2005 | EP1551416A2 Method for treating erectile dysfunction and increasing libido in men |
| 07/13/2005 | EP1551414A2 Crystal forms of olanzapine and processes for their preparation |
| 07/13/2005 | EP1551412A1 Pharmaceutical compositions for the treatment of diseases related to neurotrophines |
| 07/13/2005 | EP1551397A2 Guanidine compounds as anesthetics and for treatment of nervous system disorders |
| 07/13/2005 | EP1551395A1 5-ht 1b/1d receptor agonists for the treatment of headache resulting from administering an endothelin receptor antagonist |
| 07/13/2005 | EP1551393A2 Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions |
| 07/13/2005 | EP1551387A2 PKC ACTIVATION AS A MEANS FOR ENHANCING sAPPa SECRETION AND IMPROVING COGNITION USING BRYOSTATIN TYPE COMPOUNDS |
| 07/13/2005 | EP1551330A1 Improvements in delivery technology |
| 07/13/2005 | EP1448529B1 Sulfone derivatives suitable for the treatment of autoimmune diseases and allergies |
| 07/13/2005 | EP1432379A4 Methods for inhibiting cognitive deterioration in adults with down's syndrome |
| 07/13/2005 | EP1357898A4 Improved controlled release oral dosage form |
| 07/13/2005 | EP1235802B1 Carbamate derivatives having muscarinic receptor antagonist activity |
| 07/13/2005 | EP1207860A4 Controlled release pellet formulation |
| 07/13/2005 | EP1202722B1 Uses of compositions for treating or preventing sleep disturbances using very low doses of cyclobenzaprine |
| 07/13/2005 | EP1178969B1 Gastrin and cholecystokinin receptor ligands |
| 07/13/2005 | EP1161415B1 N-cyanomethylamides as protease inhibitors |
| 07/13/2005 | EP1152756B1 Anticonvulsant derivatives useful in treating autism |
| 07/13/2005 | EP1119363B1 Carnitine and inositol phosphate-containing composition useful as dietary supplement or drug |
| 07/13/2005 | EP1113795B1 Tryptophanyl esters and their n-acyl derivatives for the prevention and treatment of diseases caused or exacerbated by oxidation processes |
| 07/13/2005 | EP1001976B1 Peptides having potassium channel opener activity |
| 07/13/2005 | EP0977755B1 Heterocyclic compounds and their preparation and use |
| 07/13/2005 | CN1639322A Recombinant spores |
| 07/13/2005 | CN1639317A Probiotic lactobacillus salivarius strains |
| 07/13/2005 | CN1639168A Bicyclic pyridine and pyrimidine P38 kinase inhibitors |
| 07/13/2005 | CN1639165A Purine derivatives as kinase inhibitors |
| 07/13/2005 | CN1639163A Process for preparing 3-(2-(4-(6-fluorobenzo(d) isoxazol-3-yl)-piperidin-1yl)-ethyl)-2-methyl-6, 7, 8, 9-tetrahydro-4h-pyrido-(1, 2-a) pyrimidin-4-one |
| 07/13/2005 | CN1639161A Alkyne-aryl phosphodiesterase-4 inhibitors |
| 07/13/2005 | CN1639160A Process for preparing crystalline form I of cabergoline |
| 07/13/2005 | CN1639159A N-aminoacetyl-pyrrolidine-2-carbonitriles and their use as DDP-IV inhibitors |
| 07/13/2005 | CN1639156A 8'4-'3-(5-fluoro-1H-indol-3-yl)propyl!-1-piperazinyl!-2-methyl-2H-1, 4-benzoxazin -3(4H)-one methanesulfonate with high affinity for the dopamine D2 receptor and the seotonin reuptake site |
| 07/13/2005 | CN1639154A Pyranones useful as ATM inhibitors |
| 07/13/2005 | CN1639152A Pyrrole-2, 5-dione derivatives and their use as GSK-3 inhibitors |
| 07/13/2005 | CN1639141A New thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors |
| 07/13/2005 | CN1639132A N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases |
| 07/13/2005 | CN1639125A New inhibitors of histone deacetylase |
| 07/13/2005 | CN1639123A 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derativatives and their use for the treatment of pain, anxiety or gastrointestinal disorders |
| 07/13/2005 | CN1639122A Azaspiro compounds for the treatment of pain |
| 07/13/2005 | CN1639121A 3-azabicyclo (3.1.0) hexane derivatives having opioid receptor affinity |
| 07/13/2005 | CN1639115A Semicarbazide derivatives and their use as antithrombotics |
| 07/13/2005 | CN1639112A Substituted amides active at the cannabinoid-1 receptor |
| 07/13/2005 | CN1638799A Human mast cell-expressed membrane proteins |
| 07/13/2005 | CN1638796A Methods of administering anti-TNF alpha antibodies |
| 07/13/2005 | CN1638790A Compositions and methods for modulating connexin hemichannels |
| 07/13/2005 | CN1638781A Carbon monoxide as a biomarker and therapeutic agent |
| 07/13/2005 | CN1638779A Utilization of phosphatidylserine in the treatment of attention deficit syndrome (ADHS) |
| 07/13/2005 | CN1638775A Nitric oxide donors for treatment of disease and injury |
| 07/13/2005 | CN1638774A Use of desoxypeganine for treating central nervous system symptoms resulting from intoxications by psychotrops |
| 07/13/2005 | CN1638765A Mediators of Hedgehog signaling pathways, compositions and uses related thereto |
| 07/13/2005 | CN1638763A Antidepressant |
| 07/13/2005 | CN1638762A Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists |
| 07/13/2005 | CN1638760A Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin |
| 07/13/2005 | CN1638753A Potentiation of therapeutic effects of fatty acids |
| 07/13/2005 | CN1638749A Ambroxol for treating painful conditions in the mouth and pharyngeal cavity |
| 07/13/2005 | CN1638747A Sustained release pharmaceutical composition |
| 07/13/2005 | CN1638739A Compound for treating assuetude disturbance |
| 07/13/2005 | CN1638732A Sustained release drug formulations containing a carrier peptide |
| 07/13/2005 | CN1638731A Aerosol formulations for pulmonary administration of medicaments to produce a systemic effect |
| 07/13/2005 | CN1637149A Novel use |
| 07/13/2005 | CN1637010A Extraction and application of paeonol amygdaloside |
| 07/13/2005 | CN1636996A Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands |
| 07/13/2005 | CN1636993A Process for producing novel form of paroxetine hydrochloride anhydrate |
| 07/13/2005 | CN1636990A Heterocyclic substituted aminoazacycles useful as central nervous system agents |
| 07/13/2005 | CN1636983A Substituted heterocyclic compounds |
| 07/13/2005 | CN1636977A 1, 3-disubstituted pyrrolidines as alpha-2-adrenoceptor antagonists |
| 07/13/2005 | CN1636597A Compounds for the treatment of female sexual dysfunction |
| 07/13/2005 | CN1636592A Stabilized liquid polypeptide-containing pharmaceutical composition |
| 07/13/2005 | CN1636573A Vitamin-medicine composition and its use |
| 07/13/2005 | CN1636572A Compositions and methods for treatment of mitochondrial diseases |
| 07/13/2005 | CN1636565A Modified form of the r(-)-n-(4, 4-di(3-methylthien-2-yl)but-3-enyl)-nipecotic acid hydrochloride |
| 07/13/2005 | CN1636563A 噻唑衍生物 Thiazole derivatives |
| 07/13/2005 | CN1636562A Use of fluorinated triazoles in treating affective and attention disorders |
| 07/13/2005 | CN1636559A Ethers of o-desmethyl venlafaxine |
| 07/13/2005 | CN1636553A Volatile proof solid preparation and producing method thereof |
| 07/13/2005 | CN1210306C Short-chain neurotoxin of sea serpent and gene for coding it |
| 07/13/2005 | CN1210277C Heteroaryl diazabicycloalkanes, their prepn. and use |
| 07/13/2005 | CN1210274C Piperazine and piperidine derivatives |
| 07/13/2005 | CN1210273C Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods |
| 07/13/2005 | CN1210270C Novel use of phenylheteroalkylamine derivatives |
| 07/13/2005 | CN1210268C (Cyclo) alkyl substituted-gamma-aminobutyric acid derivatives (=GABA analogurs), their preparation and their use in the treatment of neurolog disorders |
| 07/13/2005 | CN1210262C Method for preparing methylsulfonate trihydrate of 1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperid-1-yl)-1-propanol |
| 07/13/2005 | CN1210261C Arylpiperidine and aryl-1,2,5,6-tetrahydropyridine amide derivatives having 5HT1A receptor activity |
| 07/13/2005 | CN1210251C Substituted nor bornylamion derivatives, method for production thereof, use thereof and medicaments containing said compounds |
| 07/13/2005 | CN1210066C Cloning pigs using donor nuclei from differentiated cells |
| 07/13/2005 | CN1210032C Parenteral formulations comprising carbamazepine or its derivatives |
| 07/13/2005 | CN1210031C Injectable slow-releasing naltrexone microsphere compositions |
| 07/13/2005 | CN1210026C Melatonin two-layer release-controlled tablet and preparing process thereof |
| 07/13/2005 | CN1210025C Tanshinone compound containing dihydrofuran ring structure for curing hyperammonemia and hepatic encephalopathy |
| 07/13/2005 | CN1210024C Crytotanshinone for preventing and delaying early senile dementia |
| 07/12/2005 | US6916961 Compound for use in the prevention and treatment of respiratory and nervous system disorders |
| 07/12/2005 | US6916941 Crystallization fromn solutions; antidepressant |
| 07/12/2005 | US6916922 Acylating a cyclopentaindolemethylamine and cyclizing and reducing the product |
| 07/12/2005 | US6916913 Dorsalin-1 polypeptide and uses thereof |
| 07/12/2005 | US6916848 Compounds for the treatment of metabolic disorders |
| 07/12/2005 | US6916838 1-benzylpyrazole-3-carboxylic acid tricyclic derivatives as cannabinoid receptor antagonists |
| 07/12/2005 | US6916835 Nitrate esters and their use for neurological conditions |
| 07/12/2005 | US6916832 Nitrogen compounds such as 8,9-dihydroxy-1,2,3,11b-tetrahydro-chromeno(4,3,2-de)isoquinoline hydrobromide, administered for prophylaxis of nervous system disorders |
| 07/12/2005 | US6916827 Central nervous system disorders |
| 07/12/2005 | US6916826 Substituted imidazo[1,2-a]pyridine derivatives |